Skip to main content
. 2020 Jun 2;12:4107–4116. doi: 10.2147/CMAR.S252664

Figure 1.

Figure 1

The ROC-AUC analyses for pretreatment ALB, pretreatment Scr, number of MTX chemotherapy courses and their joint predictor to predict severe myelosuppression with MTX chemotherapy. *Significant differences (P<0.05) of the AUC of the independent factors and joint predictor. Joint predictor=pretreatment ALB+pretreatment Scr+number of MTX chemotherapy courses.